279 related articles for article (PubMed ID: 25012652)
1. Identification and functional characterization of nuclear mortalin in human carcinogenesis.
Ryu J; Kaul Z; Yoon AR; Liu Y; Yaguchi T; Na Y; Ahn HM; Gao R; Choi IK; Yun CO; Kaul SC; Wadhwa R
J Biol Chem; 2014 Sep; 289(36):24832-44. PubMed ID: 25012652
[TBL] [Abstract][Full Text] [Related]
2. Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease.
Wadhwa R; Ryu J; Ahn HM; Saxena N; Chaudhary A; Yun CO; Kaul SC
J Biol Chem; 2015 Mar; 290(13):8447-56. PubMed ID: 25645922
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis.
Wadhwa R; Takano S; Kaur K; Deocaris CC; Pereira-Smith OM; Reddel RR; Kaul SC
Int J Cancer; 2006 Jun; 118(12):2973-80. PubMed ID: 16425258
[TBL] [Abstract][Full Text] [Related]
4. Functional significance of minor structural and expression changes in stress chaperone mortalin.
Deocaris CC; Widodo N; Ishii T; Kaul SC; Wadhwa R
Ann N Y Acad Sci; 2007 Nov; 1119():165-75. PubMed ID: 18056964
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.
Sane S; Abdullah A; Boudreau DA; Autenried RK; Gupta BK; Wang X; Wang H; Schlenker EH; Zhang D; Telleria C; Huang L; Chauhan SC; Rezvani K
Cell Death Dis; 2014 Mar; 5(3):e1118. PubMed ID: 24625977
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppression by apoptotic and anti-angiogenic effects of mortalin-targeting adeno-oncolytic virus.
Yoo JY; Ryu J; Gao R; Yaguchi T; Kaul SC; Wadhwa R; Yun CO
J Gene Med; 2010 Jul; 12(7):586-95. PubMed ID: 20603860
[TBL] [Abstract][Full Text] [Related]
7. Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells.
Wadhwa R; Takano S; Taira K; Kaul SC
J Gene Med; 2004 Apr; 6(4):439-44. PubMed ID: 15079818
[TBL] [Abstract][Full Text] [Related]
8. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
Gestl EE; Anne Böttger S
Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
[TBL] [Abstract][Full Text] [Related]
10. Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
Nigam N; Grover A; Goyal S; Katiyar SP; Bhargava P; Wang PC; Sundar D; Kaul SC; Wadhwa R
PLoS One; 2015; 10(9):e0138192. PubMed ID: 26376435
[TBL] [Abstract][Full Text] [Related]
11. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
12. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein.
Wadhwa R; Yaguchi T; Hasan MK; Mitsui Y; Reddel RR; Kaul SC
Exp Cell Res; 2002 Apr; 274(2):246-53. PubMed ID: 11900485
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member.
Wadhwa R; Takano S; Robert M; Yoshida A; Nomura H; Reddel RR; Mitsui Y; Kaul SC
J Biol Chem; 1998 Nov; 273(45):29586-91. PubMed ID: 9792667
[TBL] [Abstract][Full Text] [Related]
14. mot-2-Mediated cross talk between nuclear factor-B and p53 is involved in arsenite-induced tumorigenesis of human embryo lung fibroblast cells.
Li Y; Xu Y; Ling M; Yang Y; Wang S; Li Z; Zhou J; Wang X; Liu Q
Environ Health Perspect; 2010 Jul; 118(7):936-42. PubMed ID: 20199942
[TBL] [Abstract][Full Text] [Related]
15. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
Flachbartová Z; Kovacech B
Acta Virol; 2013; 57(1):3-15. PubMed ID: 23530819
[TBL] [Abstract][Full Text] [Related]
16. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.
Zhou R; Shanas R; Nelson MA; Bhattacharyya A; Shi J
Int J Cancer; 2010 Jan; 126(2):395-404. PubMed ID: 19609950
[TBL] [Abstract][Full Text] [Related]
18. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy.
Lu WJ; Lee NP; Kaul SC; Lan F; Poon RT; Wadhwa R; Luk JM
Cell Death Differ; 2011 Jun; 18(6):1046-56. PubMed ID: 21233847
[TBL] [Abstract][Full Text] [Related]
19. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides.
Kaul SC; Aida S; Yaguchi T; Kaur K; Wadhwa R
J Biol Chem; 2005 Nov; 280(47):39373-9. PubMed ID: 16176931
[TBL] [Abstract][Full Text] [Related]
20. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
